期刊文献+

流感减毒活疫苗中 A 型流感病毒株生产用工作毒种遗传稳定性分析 被引量:2

Analysis of the genetic stability of the master virus seeds for live attenuated influenza vaccine produc-tion
原文传递
导出
摘要 目的:分析流感减毒活疫苗的生产用工作毒种A/17/California/2009/38(H1N1)、A/17/Perth/09/87(H3N2)的遗传稳定性。方法将流感减毒活疫苗生产用工作毒种接种鸡胚尿囊腔进行传代,扩增第2、3、5、10代毒株的全基因组进行测序分析,其中每个代次的6个内部基因PB2、PB1、PA、NP、M、NS测序结果分别与冷适应供体毒株进行比对分析,血凝素( HA)和神经氨酸酶( NA)基因的测序结果分别与世界卫生组织( WHO)推荐的适用于北半球的2011—2012年流行毒株进行比对分析,从而判断疫苗生产用工作种子毒株的基因遗传稳定性。结果扩增至10代次后,H1N1疫苗毒株基因总突变率为0.035%,H3N2疫苗毒株基因总突变率为0.022%,突变位点均未发生在冷适应性( ca)、温度敏感性( ts)和减毒性( att)表型的决定位点。结论生产用工作毒种具有良好的基因遗传稳定性,扩增至第10代次的疫苗毒株同原始种子代次的同源性大于99%,工作种子批毒种符合2010年版《中华人民共和国药典》的要求。 Objective To analyze the genetic stability of master virus seed lots of live attenuated influenza vaccineA/17/California/2009/38(H1N1)andA/17/Perth/09/87(H3N2)strains.Methods The master virus seed lots were inoculated into chicken eggs for subculture.The complete genome of the 2nd, 3rd, 5th and 10th generations of viruses were amplified and sequenced.The genes encoding hemagglu-tinin ( HA) and neuraminidase ( NA) were compared with those of the WHO recommended circulating wild-type virus strains used for vaccine production in northern hemisphere during 2011-2012 influenza season.Six internal genes (PB2, PB1, PA, NP, M and NS) of each virus generation were compared with their master donor virus strain (A/Leningrad/134/17/57) for the evaluation of the genetic stability.Results The muta-tion rates of H1N1 and H3N2 strains after 10 passages were 0.035%and 0.022%, respectively.No muta-tions were found at the critical sites for controling thecold adapted ( ca) , temperature sensitive ( ts) and at-tenuated ( att) phenotypes.Conclusion The live attenuated influenza vaccine strains possessed high genet-ic stability as their tenth generations still shared 99% of homology with the original seed lots.All of the working virus seed lots met the requirements of Pharmacopoeia of the People′s Republic of China ( 2010 edition) .
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2015年第4期281-285,共5页 Chinese Journal of Microbiology and Immunology
关键词 流感减毒活疫苗 遗传稳定性 PCR Live attenuated influenza virus vaccine Genetic stability PCR
  • 相关文献

参考文献10

  • 1佘丹阳,刘又宁.流行性感冒的危害及防治[J].中华医学信息导报,2003,18(9):5-5. 被引量:1
  • 2卫生部.流行性感冒诊断与治疗指南[M].2011版.北京:卫生部,2011:35.
  • 3StanleyAP,WaiterAO,PaulAO.疫苗学[M].梁晓峰,罗风基,封多佳,等,译.5版.北京:人民卫生出版社.2011:267-317.
  • 4苗玉发,李波.4价流感活疫苗FluMist~Quadrivalent[J].中国新药杂志,2012,21(10):1069-1072. 被引量:3
  • 5Snyder MH, Betts RF, DeBorde D, et al. Four viral genes inde- pendently contribute to attenuation of live influenza A/Ann Arbor/ 6/60 (I-I2N2) cold-adapted reassortant virus vaccines[ J ]. J Vir- al, 1988, 62(2) : 488-495.
  • 6Rudenko LG, Alexandrova GI. Current strategies for the preven- tion of Influenza by the Russian cold-adaptedlive influenza vaccine among different populations [ J ]. International Congress Series, 2001, 1219 : 945-950.
  • 7Klimov AI, Cox NJ, Yotov WV, et al. Sequence changes in the live attenuated, cold-adapted variants of influenza A/Leningrad/ 134/57 (H2N2) virus[J]. Virology, 1992, 186(2):795-797.
  • 8Klimov AI, Kiseleva IV, Alexandrova GI, et al. Genes coding for polymerase proteins are essential for attenuation of the cold-adapted A/Leningrad/134/17/57 ( H2N2 ) influenza virus [ J ]. Interna- tional Congress Series, 2001, 1219:955-959.
  • 9Kiseleva IV, Klimov AI, Grigor'eva EP, et al. Genetic and phe- notypic analysis of heterogeneous popu/ation of a cold-adapted do- nor of the A/Leningrad/134/17/57 (H2N2) attenuation and of the donor-based reassortant influenza vaccine strains [ J ]. VoprVirusol, 2005, 50(2) : 14-18.
  • 10Xu X, Cox NJ, Bender CA, et al. Genetic variation in neuramini- dase genes of influenza A (H3N2) viruses[ J]. Virology, 1996, 224(1) : 175-183.

二级参考文献12

  • 1AMBROSE CS, LEVIN MJ. The rationale for quadrivalent influ- enza vaccines[J].Hum Vaccin Immunother, 2012, 8 ( 1 ) [ Epub ahead of print].
  • 2BELSHE RB. The need for quadrivalent vaccine against seasonal influenza[ J ]. Vaccine, 2010, 28 ( Suppl 4) : S45 - S53.
  • 3FDA. Package insert-FluMist^R Quadrivalent [ EB/OL ]. ( 2012 - 02 - 19 ). http ://www. fda. gov/downloads/BiologicsBloodVac- cines/Vaccines/ApprovedProducts/UCM294307, pdf.
  • 4FDA. Toxicology Review of BLA 125020 supplement1668 [ EB/ OL]. (2012 -02-19). http://www, fda. gov/downloads/Bio- logicsBloodV accines/Vaccines/ApprovedProducts/UCM295379. pdf.
  • 5EMEA. Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use out- side of the core dossier context [ EB/OL ]. (2007 - 01 - 24 ). ht- tp ://www. ema. europa, eu/docs/en_GB/document library/Sci- entific_guideline/2009/09/WC500003872, pdf.
  • 6SFDA. Guideline for vaccine preclinical safety evaluation [ EB/ OL]. (2005 - 10 - 14). http://www, sfda. gov. cn/WSOl/ CL0058/9350. html.
  • 7FDA. Guidance for industry clinical data needed to support the li- censure of pandemic influenza vaccines[ EB/OL ]. (2007 - 05 - 31 ). http://www, fda. gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegu|atoryInformation/Guidances/Vaccines/ ucm091985, pdf.
  • 8BANDELL A, WOO J, COELINGH K. Protective efficacy of live attenuated influenza vaccine (muhivalent, Ann Arbor strain) literature review addressing interference [ J ]. Expert Rev Vac cines, 2011, 10(8):1131 -1141.
  • 9BELSHE RB, COELINGH K, AMBROSE CS, et al. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity [ J]. Vaccine, 2010, 28(9) :2149 -2156.
  • 10BLOCK SL, FALLOON J, HIRSCHFIELD JA, et al. The immu- nogenicity and safety of a quadrivalent live attenuated influenza vaccine in children[J]. Pediatr Inject Dis J, 2012, [Epub a- head of print].

共引文献2

同被引文献37

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部